Preclinical Scientist/Research Associate

Reporting to: Manager of Cellular Bioscience Group
This is an exciting opportunity for a skilled research professional to join Optieum Biotechnologies, Inc., a preclinical-stage company developing next-generation CAR-T cell therapies using our proprietary Eumbody System. The successful candidate will support efforts in CAR-T evaluation and Eumbody-based clone screening for our lead candidate OPTF01 and other discovery projects.
Reporting to the manager of Cellular Bioscience Group, this individual will be responsible for executing and optimizing in vitro assays, supporting the Eumbody screening process, and helping to advance CAR-T candidates toward clinical development.

Responsibilities

• Culture T cells and tumor cell lines, including performing activation, expansion, and viral transduction.
• Conduct in vitro assays—such as cytotoxicity, cytokine release, and proliferation—to evaluate CAR-T cell function.
• Support high-throughput screening of novel Eumbody CAR clones by adhering to established protocols.
• Prepare and analyze flow cytometry panels for immune phenotyping and functional characterization.
• Maintain detailed experimental records and assist with data processing and reporting.
• Collaborate with scientists and research associates to ensure timely execution of project milestones.

Job Requirements

• Strong technical expertise in in vitro cell-based assays and immunological methods.
• Familiarity with CAR-T or other engineered immune cell systems.
• Ability to analyze and present data in a clear and organized manner.
• Excellent verbal and written communication skills in English.

Education and Skills

• Scientist: Ph.D. in Immunology, Cell Biology, Oncology, or a related field with relevant postdoctoral or industry experience.
• Research Associate: Master’s degree in a life science field with 2+ years of hands-on research experience.
• Proficiency with flow cytometry and experience in cell-based functional assays are essential.

Headquartered in Ehime, Japan, Optieum Biotechnologies, Inc. (www.optieumbio.com) is a pre-clinical stage biotechnology company committed to developing innovative CAR-T cell therapies for treating patients with cancer. Optieum’s proprietary platform technology, the Eumbody System, enables the development of advanced CAR constructs that optimize immune-cell function for human disease targets.